Get the Stockscreener App
0.66
12.02%
-0.0902
After Hours:
.66
Collplant Biotechnologies Ltd stock is traded at $0.66, with a volume of 103.46K.
It is down -12.02% in the last 24 hours and up +16.40% over the past month.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
See More
Previous Close:
$0.7502
Open:
$0.66
24h Volume:
103.46K
Relative Volume:
1.50
Market Cap:
$8.45M
Revenue:
$2.48M
Net Income/Loss:
$-12.16M
P/E Ratio:
-0.6459
EPS:
-1.0219
Net Cash Flow:
$-10.35M
1W Performance:
+8.20%
1M Performance:
+16.40%
6M Performance:
-78.98%
1Y Performance:
-75.60%
1-Day Range:
$0.6162
$0.85
1-Week Range:
$0.58
$0.85
52-Week Range:
$0.495
$4.98
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
Collplant Biotechnologies Ltd
Sector
Industry
Phone
-
Address
-
Compare CLGN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
0.66 | 9.60M | 2.48M | -12.16M | -10.35M | -1.0219 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-23 | Initiated | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Stock (CLGN) Latest News
Collplant Biotechnologies Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
CollPlant Biotechnologies (NASDAQ:CLGN) Stock Surges on Q4 Revenue Beat - ChartMill
COLLPLANT BIOTECHNOLOGIESNEW ($CLGN) Releases Q4 2025 Earnings - Quiver Quantitative
CollPlant Biotechnologies (NASDAQ: CLGN) 20-F warns on going concern and cash - Stock Titan
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PR Newswire
CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Profit Outlook - simplywall.st
CollPlant Biotechnologies Faces Nasdaq Bid-Price Deficiency, Granted Compliance Window - TipRanks
CollPlant (CLGN) receives Nasdaq minimum bid-price notice, given time to cure - Stock Titan
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement - PR Newswire
CollPlant Biotechnologies (CLGN) CEO Tal Yehiel details option and RSU holdings - Stock Titan
CollPlant (CLGN) director Alisa Lask details option and RSU holdings - Stock Titan
CollPlant Biotechnologies (CLGN) director reports options and RSUs on Form 3 - Stock Titan
CollPlant Biotechnologies (CLGN) director details option and RSU stake - Stock Titan
CollPlant (CLGN) VP reports 25,000 RSUs with 4-year vesting - Stock Titan
CollPlant (NASDAQ: CLGN) VP Legal details options and RSU awards - Stock Titan
CollPlant (CLGN) VP details option and restricted share unit holdings - Stock Titan
CollPlant (NASDAQ: CLGN) VP discloses options, RSUs and shares in Form 3 - Stock Titan
CollPlant (CLGN) VP details options and RSUs stake - Stock Titan
CollPlant Biotechnologies (NASDAQ: CLGN) deputy CEO details option and RSU stakes - Stock Titan
CollPlant Biotechnologies Launches Redesigned Corporate Website - Finviz
CollPlant Biotechnologies Launches Redesigned Corporate Website - Benzinga
Reviewing CG Oncology (NASDAQ:CGON) and CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS - Finviz
Biotech CollPlant to unveil 2025 results before U.S. market open - Stock Titan
CLGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler - Intellectia AI
CollPlant secures Korean patent for dermal filler technology - Investing.com Australia
Collplant Biotechnologies Announces Korean Patent Allowance Secured for Its Photocurable Dermal Filler - marketscreener.com
CollPlant (CLGN) Receives Korean Patent for Dermal Filler Techno - GuruFocus
CollPlant Secures Korean Patent Allowance for Photocurable Dermal Filler Platform - TipRanks
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler - Revista ADVFN
CollPlant launches BioFlex bioink kit for 3D bioprinting By Investing.com - Investing.com India
CollPlant Launches BioFlex rhCollagen Bioink Kit to Advance 3D Bioprinting - The Globe and Mail
CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference - Intellectia AI
BioFlex launch expands CollPlant (NASDAQ: CLGN) 3D bioprinting portfolio - Stock Titan
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex - Barchart.com
What’s the outlook for CollPlant Biotechnologies Ltd.’s sectorRate Hike & High Win Rate Trade Alerts - mfd.ru
CollPlant Moves to Capture GLP-1-Driven Aesthetic Market With Photocurable rhCollagen Filler - TipRanks
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments - marketscreener.com
New rhCollagen filler targets faces thinned by GLP-1 weight loss - Stock Titan
What is CollPlant Biotechnologies Ltd. s debt to equity ratioJuly 2025 Sentiment & Weekly High Conviction Ideas - mfd.ru
A | Does CollPlant Biotechnologies Ltd. stock have upside surprise potential - mfd.ru
Will CollPlant Biotechnologies Ltd. stock rally after Fed decisionsJuly 2025 Review & Daily Stock Momentum Reports - mfd.ru
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Turn A Profit? - Yahoo Finance
CollPlant stock rating downgraded to Hold from Buy by D. Boral Capital - Investing.com Australia
CollPlant Biotechnologies Raises $2 Million in Registered Direct Offering with Concurrent Warrant Placement - TipRanks
This Impinj Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga
CollPlant (CLGN) to raise about $2.0M via direct share sale and warrants - Stock Titan
CollPlant to sell 1.6M ordinary shares at $1.25 in registered direct offering - Yahoo Finance
United States shares lower at close of trade; Dow Jones Industrial Average down 1.20% By Investing.com - Investing.com India
Collplant Biotechnologies Ltd Stock (CLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):